AI For Humans: Making Artificial Intelligence Fun & Practical AI Creates New Drugs As OpenAI & NVIDIA Shuffle Billions
121 snips
Sep 26, 2025 Discover how AI is reshaping drug design with non-hallucinogenic psychedelics, enhancing mood-targeting therapies. Tune into discussions about NVIDIA's massive funding for OpenAI and its ambitious compute infrastructure. Hear the social impact of ChatGPT, including its surprising effects on relationships. Explore breakthrough advancements in video and music generation with new AI models while contemplating the potential of an AI bubble. Plus, catch a sneak peek of the hosts' exciting new startup, AndThen!
AI Snips
Chapters
Transcript
Episode notes
AI-Designed Nonhallucinogenic Psychedelics
- Mindstate Design Labs used AI to design non-hallucinogenic psychedelics aimed at therapeutic benefits without trips.
- They trained on 70,000+ trip reports and clinical sources to create compounds that heighten emotion and imagination while minimizing hallucinations.
AI Enables Scalable Personalized Medicine
- Personalized medicine becomes more feasible as AI can tailor compounds to individual genetics and life history.
- Combining human clinicians with AI-designed drugs could deliver highly targeted mental-health treatments.
Massive Spend For AI Infrastructure
- OpenAI and NVIDIA structured a $100B arrangement that effectively funnels cash back into NVIDIA chips for OpenAI data centers.
- Sam Altman says 10 GW is only the start and they may need vastly more power to reach "abundant intelligence."